Company profile
Acadia Pharmaceuticals
Pipeline6 assets
- RemlifanserinACP-204 / 5-HT2A receptor / inverse agonist / Neurological DisordersAlzheimer’s Disease PsychosisPhase 2RecruitingLewy Body Dementia with PsychosisPhase 2
- ACP-211ACP-211 / selectively deuterated R-norketamine / Neurological DisordersMajor Depressive DisorderPhase 2
- ACP-711ACP-711 / GABAA α3 / modulator / Neurological DisordersEssential TremorPhase 1
- ACP-271ACP-271 / GPR88 / agonist / Neurological Disorders; Rare DiseasesTardive DyskinesiaIND EnablingHuntington's DiseaseIND Enabling
- ACP-2591ACP-2591 / cGP analog / Rare DiseasesRett Syndrome; Fragile X SyndromePhase 1
- STOKE ASOantisense oligonucleotide / Rare DiseasesSYNGAP1Discovery